Elsevier

Clinica Chimica Acta

Volume 412, Issues 9–10, 11 April 2011, Pages 793-795
Clinica Chimica Acta

Letter to the Editor
Comparison of Two Assays for Serum 1,5-Anhydroglucitol

https://doi.org/10.1016/j.cca.2011.01.007Get rights and content

Section snippets

Acknowledgments

Dr. Selvin was supported by NIH/NIDDK grant K01 DK076595. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The authors thank the staff and participants of the ARIC study for their important contributions. Kyowa Medex provided in-kind support (reagents). The authors thank Dr. Kunihiro Matsushita

References (7)

There are more references available in the full text version of this article.

Cited by (22)

  • Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial

    2021, Diabetes Research and Clinical Practice
    Citation Excerpt :

    Limitations include the high prevalence of CVD (33%) due to trial eligibility criteria that included CVD history or > 1 CVD risk factor [13,14], and the single baseline measurement of 1,5-AG and the cardiac biomarkers. Biomarkers were measured after ∼ 15 years of freezer storage, however prior research suggests the validity and reliability of these measurements in long-term stored samples [16–19]. Our results suggest that monitoring cardiac markers provides more prognostic information regarding vascular risk than 1,5-AG.

  • Review of methods for detecting glycemic disorders

    2020, Diabetes Research and Clinical Practice
    Citation Excerpt :

    Earlier studies demonstrated that the plasma concentration of 1,5-AG could be a marker of previous (1–2 weeks) exposure to hyperglycemia above the glucose renal threshold, reflecting post-prandial hyperglycemic peaks [332,333]. Automated and quantitative 1,5-AG measurements can be performed using commercially available biochemical assay kits [334–336]. FDA approved this marker for monitoring intermediate-term glycemic control in those with diabetes and post-prandial hyperglycemia [337].

  • Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study

    2018, Atherosclerosis
    Citation Excerpt :

    Fructosamine (Roche Diagnostics Corp, Indianapolis, IN, USA), glycated albumin (Asashi Kasei Lucica GA-L, Tokyo, Japan), and 1,5-AG (GlycoMark, Winston-Salem, NC) were measured in 2012–2013 in stored frozen serum using a Roche Modular P800 system [14,18]. Previous studies have shown these analytes to be reliable in long-term stored samples [19–21]. Age, gender, race, educational level, alcohol use, and smoking status were self-reported.

  • Clinical and forensic examinations of glycemic marker 1,5-anhydroglucitol by means of high performance liquid chromatography tandem mass spectrometry

    2012, Forensic Science International
    Citation Excerpt :

    Glycated hemoglobin (HbA1c) – although very stable after death [10] – is not a good indicator of glycemic control over shorter periods. For the determination of 1,5-AG in clinical serum samples, two commercially available enzymatic assays exist, the GlykoMark® assay [4] and the Determiner-l-1,5-AG® (Kyowa Medex, Japan) [11] which were compared recently, both showing comparable results [12]. In these assays, a hydrogen peroxide by-product is detected colorimetrically using a standard peroxidase assay after the oxidation of 1,5-AG to 1,5-anhydrofuctose by pyranose oxidase.

View all citing articles on Scopus
View full text